Developing effective treatments for patients with Huntington's disease (HD)—a
neurodegenerative disorder characterized by severe cognitive, motor and psychiatric …

This article presents an overview of imaging agents for PET that have been applied for
research and diagnostic purposes in patients affected by dementia. Classified by the target …

Tau PET tracers exhibit varying levels of specific signal and distinct off-target binding
patterns that are more diverse than amyloid PET tracers. This study compared 2 frequently …

Recent studies in cognitively unimpaired elderly individuals suggest that the APOE ε4 allele
exerts a dosage-dependent effect on brain tau deposition. The aim of this study was to …

The strongest genetic risk factor for Alzheimer's disease (AD) is the Apolipoprotein E type 4
allele (ApoE ε4). The interaction between sex and ApoE ε4 carrier status on AD risk remains …

Background: Elevated blood pressure variability (BPV) is predictive of dementia,
independent of average blood pressure levels, but neuropathological mechanisms remain …

Tau proteins accumulation and their spreading pattern were affected by gender in cognitive
impairment patients, especially in the progression of Alzheimer's disease (AD). However, it …

It has been estimated that every year, millions of people are affected by neurodegenerative
disorders, which complicate their lives and their caregivers' lives. To date, there has not …

Given the prevalence of dementia and the development of pathology-specific disease-
modifying therapies, high-value biomarker strategies to inform medical decision-making are …

Objective To evaluate temporal correlations between CSF and neuroimaging (PET and MRI)
measures of amyloid, tau, and neurodegeneration in relation to Alzheimer disease (AD) …